Inhibrx Biosciences (INBX) vs Replimune Group (REPL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Inhibrx Biosciences is the larger company by market cap ($1.37 billion vs $1.24 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INBX | REPL |
|---|---|---|
| Share price | $93.36 | $13.20 |
| Market cap | $1.37B | $1.24B |
| 1-day change | -0.05% | -0.38% |
| YTD return | — | +35.80% |
| 1-year return | — | +183.87% |
| 5-year return | — | -56.22% |
| EPS (TTM) | $-8.88 | $-3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $155.29 | $16.33 |
| 52-week low | $28.16 | $1.50 |
| Distance from 52-week high | -39.88% | -19.17% |
| Average volume | 296.25K | 4.20M |
| Shares outstanding | 14.72M | 94.22M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
INBX vs REPL FAQ
Which is bigger, Inhibrx Biosciences or Replimune Group?
Inhibrx Biosciences (INBX) is larger, with a market capitalization of $1.37B compared with $1.24B for Replimune Group (REPL).
Are Inhibrx Biosciences and Replimune Group in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.